Amicus Therapeutics

Amicus Therapeutics is now part of BioMarin Pharmaceutical Inc. Follow @BioMarin for updates

[Amicus Therapeutics @amicusrx1]

As we continue our integration into BioMarin, we are retiring this channel on June 12.

We invite you to continue the journey with us by following @BioMarin, where our mission carries on with even greater reach and possibility.

Thank you for being an important part of our story.

[Amicus Therapeutics @amicusrx1]

Today we officially became part of @BioMarin . We look forward to continuing to deliver transformative medicines for people living with rare diseases. Please follow BioMarin to continue with us on this journey.

Read more: https://t.co/ZFOSETjrqU

[Amicus Therapeutics @amicusrx1]

Thanks to everyone who joined our #NHSConfedExpo poll! The correct answer was C. People living with a rare disease.

1 in 17 people in the UK live with a rare condition. We must continue to listen, learn, and take action to address the health inequities they face.

[Amicus Therapeutics @amicusrx1]

To coincide with our presence at #NHSConfedExpo, we'd love your input on this:
Of the following groups, which do you think there are more of living in the UK?

NP-NN-ALL-00100525 | May 2025

[Amicus Therapeutics @amicusrx1]

Our team made a strong impact at #NHSConfedExpo, with sessions focused on addressing the health inequalities faced by the #RareDisease community.

Thanks to our speakers and all who joined us, visited our stand, and contributed to our live mural.
#ClosingTheCareGap #AmicusCares

[Amicus Therapeutics @amicusrx1]

To coincide with our presence at #NHSConfedExpo, we'd love your input on this:
Of the following groups, which do you think there are more of living in the UK?

NP-NN-ALL-00100525 | May 2025

[Amicus Therapeutics @amicusrx1]

We’re heading to #NHSConfedExpo in Manchester UK! Catch our two sessions on closing the care gap in rare diseases and visit our stand to help create a live mural highlighting health inequality.

Look forward to seeing you there!
#AmicusTherapeutics #ClosingTheCareGap #AmicusCares

[Amicus Therapeutics @amicusrx1]

We are thrilled to announce the expansion of our pipeline with the U.S. licensing of DMX-200 to bring even more hope to people living with rare diseases. Read more here: https://t.co/vn0mFFyDAR

[Amicus Therapeutics @amicusrx1]

The journey to a #Fabry disease diagnosis can be long and complex. Watch Dr James O’Donovan sit down with Loretta MacInnes to discuss the challenges of diagnosis.
Full video: https://t.co/ADDsAo31W1… #amicuscares #CouldItBeFabryNP-
NN-IN-00010325

[Amicus Therapeutics @amicusrx1]

With the vital help of our patient community partners, we are thrilled to see our study published emphasizing the importance of understanding the quality of life and lived experiences of those with late-onset Pompe disease (#LOPD).

https://t.co/GaPqOnLAap

[Amicus Therapeutics @amicusrx1]

We’re presenting our Q4 and Full Year 2024 results today at 8.30am ET on a live audio webcast with our President and Chief Executive Officer Bradley Campbell.
Find out more here: https://t.co/JNATvgxKpw
#Earnings #AmicusTherapeutics

[Amicus Therapeutics @amicusrx1]

We are excited to join with the lysosomal diseases community at this year’s @worldsymposium . Together, we’ve made remarkable progress in the fight against rare diseases. And together, we can do even more. Patients are counting on us -- all of us.

#WORLDSymposia #RareDiseases

[Amicus Therapeutics @amicusrx1]

Today the UK based Office of Health Economics (OHE) has published a report, funded by Amicus, on the need for supplier diversity in rare disease markets.

[Office of Health Economics @OHENews]

Can diversity of supply in rare disease markets improve patients’ health and health system efficiency? Reliance on a single -supplier leaves patients vulnerable to shortages and limited choices. Read more: https://t.co/jWCLXLuZXN

[Amicus Therapeutics @amicusrx1]

#JPM25 has been a great opportunity to connect with others in the industry to see what difference we can make for patients, performance, and partnering. Missed our live webcast updating on our successes from 2024? Listen via the following link: https://t.co/OrO83lb8KU

[Amicus Therapeutics @amicusrx1]

In November, Team Amicus took on the Rocky Run half marathon to raise awareness and funds for @wishnj. Together with Fight Like Frankie, we had the honor of visiting the Make-A-Wish Castle to present our donation- a testament to the power of community and commitment! #AmicusCares

[Amicus Therapeutics @amicusrx1]

We’re presenting today at #JPM25 at 3pm PT / 6pm ET. Follow the link below for the live audio webcast with our President and Chief Executive Officer Bradley Campbell. https://t.co/K21nnTOky6

[Amicus Therapeutics @amicusrx1]

At #JPM25 today, Amicus President and Chief Executive Officer Bradley Campbell will highlight our accomplishments in 2024 and share what’s ahead for our company in 2025. Learn more here: https://t.co/9VyDTerHyJ

[Amicus Therapeutics @amicusrx1]

Today we announced our preliminary full-year 2024 results and what’s ahead for our company in 2025. Learn more here: https://t.co/9VyDTer9Jb

[Amicus Therapeutics @amicusrx1]

As we welcome 2025, we remain steadfast in our commitment to improving the lives of people living with #rarediseases. Here’s to a year filled with hope, collaboration, and advancements for the rare disease community.

#HappyNewYear from everyone at Team Amicus!

#AmicusCares

[Amicus Therapeutics @amicusrx1]

Amicus Therapeutics will be participating in the 43rd Annual J.P. Morgan Healthcare Conference.

Join us for a presentation delivered by Bradley Campbell, President and Chief Executive Officer on Monday, January 13, 2025, at 3:00 p.m. PT

https://t.co/WenTpmserk

#JPM25

[Amicus Therapeutics @amicusrx1]

From all of us at Amicus, we wish you and your loved ones a joyful holiday season and a hopeful, healthy new year!

#HappyHolidays #RareDisease #AmicusCares